Renalytix AI PLC Update on non-executive director appointment (0454O)

TIDMRENX

RNS Number : 0454O

Renalytix AI PLC

30 September 2019

Renalytix AI plc

("RenalytixAI" or the "Company")

Update on non-executive director appointment

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that it expects to appoint an additional non-executive director and healthcare industry veteran within the coming weeks.

A qualified candidate has been identified to the Company and the process of completing regulatory due diligence is nearing completion. Further announcements will be made at the appropriate time.

For further information, please contact:

 
Renalytix AI plc                                                          www.renalytixai.com 
James McCullough, CEO                                                         Via Walbrook PR 
 
Stifel (Nominated Adviser & Joint Broker)                                  Tel: [phone] 
Alex Price / Jonathan Senior / Ben Maddison 
 
N+1 Singer (Joint Broker)                                                  Tel: [phone] 
Aubrey Powell / George Tzimas (Corporate Finance) 
 Tom Salvesen / Mia Gardner (Corporate Broking) 
 
Walbrook PR Limited                            Tel: [phone] or [e-mail] 
Paul McManus / Lianne Cawthorne                                Mob: [phone] 
                                                                                          303 
 
 

About Kidney Disease

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have chronic kidney disease. It is reported that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

For more information, visit renalytixai.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

UPDLLMRTMBJTBAL

(END) Dow Jones Newswires

September 30, 2019 03:00 ET (07:00 GMT)